Microsclerotherapy Treatment Market Size, Share, Trends, Growth 2028

Microsclerotherapy Treatment Industry Perspective:

The global microsclerotherapy treatment market was size worth USD 6,829.4 million in 2021 and is estimated to grow to USD 8,154.6 million by 2028, with a compound annual growth rate (CAGR) of approximately 3.0 percent during the forecast period.

The report analyzes the microsclerotherapy treatment market's drivers, restraints/challenges, and their effect on the demands during the projection period. In addition, the report explores emerging opportunities in the microsclerotherapy treatment market.

Request Free Sample

Microsclerotherapy Treatment Market: Overview

Telangiectasia, a disorder where ruptured blood vessels close to the surface or mucous membrane appear as red or pink lines on the skin surface, is treated with microsclerotherapy. Both genetic and environmental factors influence Telangiectasia. Telangiectasia may also be brought on by aging, pregnancy, rosacea, excessive sun exposure, and varicose veins. Although there is no treatment for this illness, it can be managed using microsclerotherapy.

One of the primary driving factors influencing the growth of the worldwide microsclerotherapy market is the increasing prevalence of spider and varicose veins. The relatively painless treatment, low invasion, high effectiveness, fewer post-operative problems, and simple analgesia needed during the treatment are essential elements that propel the global market forward. Spider veins are more common in the elderly population.

Therefore, an increase in the geriatric population is yet another aspect that can positively impact the global market. Additionally, obesity, the prevalence of unhealthy lifestyles, and heredity throughout the projected period may impact the expansion of the worldwide microsclerotherapy market.

The increased cost of therapy, a lack of surgeon training, and other alternative methods are the major factors that may restrict the worldwide market growth.

COVID-19 Impact:

During the COVID-19 lockdown, public and commercial institutions stopped caring for patients with varicose veins and associated problems. The frequency of varicose vein procedures has declined dramatically due to a lack of anesthetic sessions, with anesthetists being busy with emergency patients, whether COVID or non-COVID.

Additionally, venous illnesses such as varicose veins are typically more likely to develop in the elderly population and those with co-morbid conditions. As a result, most interventions connected to varicose vein treatment are reserved and postponed during the outbreak, likely impacting the market growth substantially.

Request Free Sample

To know more about this report, request a free sample copy.

Key Insights

• As per the analysis shared by our research analyst, the global microsclerotherapy treatment market value will grow at a CAGR of 3.0% over the forecast period.
• In terms of revenue, the global microsclerotherapy treatment market size was valued at around USD 6,829.4  million in 2021 and is projected to reach USD 8,154.6 million by 2028.
• High technological developments for treating venous diseases, a growing global elderly population with an increased prevalence of varicose veins, and high demand for less invasive procedures are the main factors propelling the microsclerotherapy treatment market growth.
• By product type, the sclerosants category dominated the market in 2021.
• By end users, the hospital’s category dominated the market in 2021.
• North America dominated the global microsclerotherapy treatment market in 2021.

Microsclerotherapy Treatment Market: Growth Drivers

The rise in the prevalence of varicose veins among women drives the market growth

One of the primary driving factors influencing the growth of the global microsclerotherapy treatment market is the increasing prevalence of spider and varicose veins. The global prevalence of varicose veins will rise dramatically in the next years. According to a survey by the Occupational Health & Safety Research Institute, the prevalence of varicose veins in the lower limbs varies between 10% and 30% worldwide.

The prevalence of varicose veins is much higher in women than in men. Pregnancy and repeated deliveries are the primary risk factors for spider veins in women due to increased expression of hormonal substances such as estrogen and progesterone. Varicose veins affect 55% of women and 45% of males.

The key factors further propelling the market's growth are relatively painless treatments, minimal invasion, high effectiveness, fewer post-operative side effects, and simple anesthesia required during the procedure.

Microsclerotherapy Treatment Market: Restraints

High treatment costs and adverse treatment effects hinder the market growth

Adverse effects and expensive treatment costs are expected to hinder the global microsclerotherapy treatment market's expansion. Matting and persistent pigmentation have been observed as side effects of microsclerotherapy by 1–10% of patients, as per the Journal of Phelbolymphology. The treatments are costly, ranging from USD 600 - 1200, and the price is based on the size of the vein, with at least 2 to 6 treatment periods required at 4 to 6-week intervals. The process is a little difficult, and patients may find wearing a compression bandage for several weeks after surgery uncomfortable. Lack of training for surgeons is another factor that hinders market growth.

Microsclerotherapy Treatment Market: Segmentation

The global microsclerotherapy treatment market has been segmented into product type, end users, and region.

Based on product type, the sclerosants, sodium tetradecyl sulphate, polidocanol, chromated glycerin, hypertonic glucose, needles, and others are segments of the global microsclerotherapy treatment market. Among these, the sclerosants segment dominated the global market in 2021. Major manufacturers' commercialization and development of new sclerosants for the therapy of spider veins, such as polidocanol, sodium tetradecyl sulphate, and hypertonic saline, are accelerating segment expansion.

Based on end users, the market is classified into hospitals, aesthetic treatment clinics, and others. In 2021, the hospital category dominated the global market owing to a rise in the rate of hospitalization for spider veins and the wide variety of services given by hospitals in a centralized location.

Recent Developments

• May 2022: THERACLION has announced the release of SONOVEIN HD, a scalable robotic system for non-invasive ecotherapy. This ground-breaking technology combines the first extracorporeal treatment ultrasound solution with the cutting-edge imaging capabilities of Hologic's acquisition of SuperSonic Imagine.
• October 2020: Theraclion's second-generation SONOVEINS HIFU therapy product for varicose veins has acquired CE mark clearance. Additionally, it has partnered strategically with SuperSonic Imaging as a supplier.

Microsclerotherapy Treatment Market: Report Scope

Microsclerotherapy Treatment Market: Regional Landscape

North America dominated the microsclerotherapy treatment market in 2021

Due to advanced healthcare facilities, an increasing emphasis on aesthetics, persistent lifestyle modifications, the prevalence of varicose veins, and a rise in disposable income, North America dominates the global microsclerotherapy treatment market. The presence of major players in the market and well-developed healthcare infrastructure in nations such as the U.S. and Canada are major factors driving the growth of the spider veins treatment industry in North America. Additionally, Americans can get this treatment at a reasonable cost because of the favorable reimbursement scenario. Furthermore, the existence of important players, early adoption of advanced technologies, and increased R&D activities are expected to propel the regional market.

Microsclerotherapy Treatment Market: Competitive Landscape

Some of the main competitors dominating the global microsclerotherapy treatment market include -

• Merz Pharma GmbH & Co. KGaA
• Surgimedix Inc
• Troikaa
• QOL Medical LLC
• McKesson Corporation
• Kreussler Inc
• Provensis, ltd
• Omega Pharmaceuticals
• STD Pharmaceuticals Product Ltd
• Medtronic Plc
• Endo-Flex
• Boston Scientific Corporation
• Teleflex Incorporated

Global Microsclerotherapy Treatment Market is segmented as follows:

By Product Type

• Sclerosants
• Sodium Tetradecyl Sulphate
• Polidocanol
• Chromated Glycerin
• Hypertonic Glucose
• Needles
• Others

By End Users

• Hospitals
• Aesthetic Treatment Clinics
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa